CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans

Neuroscience Letters

Volumn 504, Issue 3, 2011, Pages 336-338

  Spies, Petra E ^a   Slats, Diane ^a   Olde Rikkert, Marcel G M ^a   Tseng, Jack ^b   Claassen, Jurgen A H R ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Synuclein; Alzheimer disease; Amyloid beta peptide; Biomarker; Cerebrospinal fluid; Dementia with Lewy bodies

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; AGING; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 82455167944     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.09.063     Document Type: Article

References (10)

1. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2011, 10.1016/j.neurobiolaging.2010.12.001.
2. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666-669.
3. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., Montine T.J., Hancock A.M., Hwang H., Pan C., Bradner J., Kang U.J., Jensen P.H., Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
4. Kazmierczak A., Strosznajder J.B., Adamczyk A. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem. Int. 2008, 53:263-269.
5. Mandal P.K., Pettegrew J.W., Masliah E., Hamilton R.L., Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem. Res. 2006, 31:1153-1162.
6. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
7. Slats D., Claassen J.A., Spies P.E., Borm G.F., Besse K.T.C., van Aalst W., Tseng J., Sjogren J.M., Olde Rikkert M.G., Verbeek M. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer Disease and healthy older volunteers. Neurobiol. Aging 2011, 10.1016/j.neurobiolaging.2011.07.008.
8. Spies P.E., Melis R.J., Sjogren M.J., Rikkert M.G., Verbeek M.M. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 2009, 16:363-369.
9. van Geel W.J., Abdo W.F., Melis R., Williams S., Bloem B.R., Verbeek M.M. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 2008, 168:182-185.
10. Waring J., Slats D., Gonzales C., Dean R., Lee D., Siemers E., Claassen J.A., Li J., LeBlond D., Slemmon R., Bateman R.J., Tong G., Fox G. An assessment of variability in CSF biomarkers in clinical experimental models: a meta-analysis. Alzheimers Dement. 2011, 7:S100.